Just lovin it

Just lovin it

Who knew that Valentine’s Day this Hallmark holiday would provide Diabetic Investor so much love? We’ve always known that wacky world of diabetes is the gift that keeps on giving but honestly today our cup has runneth over. Take a look at our latest gift from our friends at Bloomberg;

“Olivier Brandicourt, who runs Bayer AG’s health-care business, is a frontrunner to become chief executive officer of Sanofi as France’s biggest drugmaker moves toward appointing a new leader by March, people with knowledge of the company’s strategy said.”

If true our favorite acting CEO and quote machine Serge Weinberg can go back to inserting his foot in his mouth and stop worrying about how to fix the soap opera he and the board created.

Now Diabetic Investor must confess we don’t know Mr. Brandicourt who according to his bio

“Dr. Olivier Brandicourt has been Chief Executive Officer and Chairman of the Board of Management of Bayer HealthCare AG since 2013. Brandicourt is responsible for leading the company’s diversified healthcare portfolio globally, encompassing pharmaceuticals, consumer care, animal health and medical care businesses.

A physician by training, Brandicourt spent eight years with the Institute of Infectious and Tropical Diseases at the Pitié-Salpêtrière Hospital in Paris with a focus on malaria research in West and Central Africa. He also spent two years in the Republic of Congo as a doctor.”

Yet reading this bio we were glad to see his French Connection, not the great movie with Gene Hackman, but his stint in Paris at the Pitié-Salpêtrière Hospital. Heck only in France can the name of a hospital sound so damn sexy, but we digress.

We were also pleased that Mr. Brandicourt will bring with him some diabetes experience as he oversees Bayer’s beleaguered for sale again diabetes device unit. A unit that Sanofi (NYSE:SNY) was to buy only to shy away only to fall back in love only to fall back out of love with.

Given this set of circumstances Diabetic Investor has an idea, Sanofi shouldn’t just hire Mr. Brandicourt as CEO but they should buy the diabetes unit too. According to the Bloomberg story a sticking point in getting Mr. Brandicourt might be “unwinding contractual obligations at Leverkusen, Germany-based Bayer”.  Think about this for a moment as Bayer just might let Mr. Brandicourt go if Sanofi threw in a few billion for the diabetes unit.  Come on Serge your still CEO show Bayer a little love to get the man of your dreams. One last act to prove conclusively that you’re a better wine drinker than CEO.

Now before everyone gets too exited keep in mind that this Sanofi we’re talking about, a company not exactly known for solid execution. A company as we noted above cannot seem to pull the trigger on a deal unless of course it’s a really bad one like MannKind (NASDAQ:MNKD), yet we digress again.

So in the spirit of Valentine’s Day when love is in the air, we’ll show our wine drinking friends a little love today and congratulate them, albeit prematurely (and boy could we have fun with that last line but Diabetic Investor is family publication and anything that happens prematurely can’t be that satisfying) on finding their man. We’ll also show some additional love and congratulate Mr. Brandicourt for being the apple, or more appropriately the chardonnay, of Sanofi’s eye. Yes in the spirit of this Hallmark holiday no snide remarks, no nasty comments and no piling on – there will plenty of time for that after the holiday.